Dylan A Frabutt
Overview
Explore the profile of Dylan A Frabutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang J, Frabutt D, Chrzanowski M, Li N, Miller L, Tian J, et al.
Mol Ther Methods Clin Dev
. 2024 Feb;
32(1):101206.
PMID: 38390555
Self-complementary AAV vectors (scAAV) use a mutant inverted terminal repeat (mITR) for efficient packaging of complementary stranded DNA, enabling rapid transgene expression. However, inefficient resolution at the mITR leads to...
2.
Zhang J, Chrzanowski M, Frabutt D, Lam A, Mulcrone P, Li L, et al.
J Med Virol
. 2022 Dec;
95(1):e28433.
PMID: 36571262
Recombinant adeno-associated virus (rAAV) vectors carry a cassette of interest retaining only the inverted terminal repeats (ITRs) from the wild-type virus. Conventional rAAV production primarily uses a vector plasmid as...
3.
Mulcrone P, Zhang J, Pride P, Lam A, Frabutt D, Ball-Kell S, et al.
Adv Cell Gene Ther
. 2022 Dec;
2022.
PMID: 36507314
Recombinant AAV (rAAV) gene therapy is being investigated as an effective therapy for several diseases including hemophilia B. Reports of liver tumor development in certain mouse models due to AAV...
4.
Zhang J, Guo P, Yu X, Frabutt D, Lam A, Mulcrone P, et al.
Mol Ther Nucleic Acids
. 2022 Sep;
29:852-861.
PMID: 36159586
Recombinant adeno-associated virus (rAAV) vectors have been developed for therapeutic treatment of genetic diseases. Current rAAV vectors administered to affected individuals often contain vector DNA-related contaminants. Here we present a...
5.
Chai Q, Li S, Collins M, Li R, Ahmad I, Johnson S, et al.
Cell Rep
. 2021 Aug;
36(6):109514.
PMID: 34380030
HIV-1-negative factor (Nef) protein antagonizes serine incorporator 5 (SERINC5) by redirecting this potent restriction factor to the endosomes and lysosomes for degradation. However, the precise mechanism remains unclear. Using affinity...
6.
Zhang X, Shi J, Qiu X, Chai Q, Frabutt D, Schwartz R, et al.
J Virol
. 2019 May;
93(14).
PMID: 31043528
Serine incorporator 5 (SERINC5) is a recently identified restriction factor that strongly blocks HIV-1 entry but is counteracted by Nef. Notably, tier 1 HIV-1 Env proteins are sensitive to SERINC5,...
7.
Frabutt D, Wang B, Riaz S, Schwartz R, Zheng Y
J Virol
. 2017 Oct;
92(1).
PMID: 29046440
Innate immunity provides an immediate defense against infection after host cells sense danger signals from microbes. Endoplasmic reticulum (ER) stress arises from accumulation of misfolded/unfolded proteins when protein load overwhelms...
8.
Zhang X, Zhou T, Yang J, Lin Y, Shi J, Zhang X, et al.
J Virol
. 2017 Mar;
91(10).
PMID: 28275190
Among the five serine incorporator (SERINC) family members, SERINC5 (Ser5) was reported to strongly inhibit HIV-1 replication, which is counteracted by Nef. produces 5 alternatively spliced isoforms: Ser5-001 has 10...
9.
Wang B, Wang Y, Frabutt D, Zhang X, Yao X, Hu D, et al.
J Biol Chem
. 2017 Feb;
292(14):5860-5870.
PMID: 28196864
The Ebola virus (EBOV) trimeric envelope glycoprotein (GP) precursors are cleaved into the receptor-binding GP and the fusion-mediating GP subunits and incorporated into virions to initiate infection. GP and GP...
10.
Frabutt D, Zheng Y
Viruses
. 2016 Sep;
8(9).
PMID: 27657106
Enveloped viruses represent a significant category of pathogens that cause serious diseases in animals. These viruses express envelope glycoproteins that are singularly important during the infection of host cells by...